Navigating Cytomegalovirus Retinitis in a Patient With Myelodysplastic Syndromes Transitioning to Acute Myeloid Leukemia Post Transplant: A Case Study. (PubMed, Cureus) - Mar 7, 2025 - "Her UL97 resistance posed significant challenges to CMV management, necessitating a transition from ganciclovir to foscarnet and maribavir. The CMV polymerase chain reaction (PCR) levels initially >10,000 copies/mL decreased to <300 copies/mL with combination therapies, though fluctuations persisted until letermovir prophylaxis was initiated. Six months after the transplant, AML relapse was treated with cladribine, cytarabine, granulocyte-colony-stimulating factor/filgrastim, and mitoxantrone (CLAG-M) and venetoclax, leading to measurable clearance of TP53 mutations to undetectable levels by NGS and reduction of CD34+ blasts from 25% to 0%...This case illustrates the aggressive nature of MDS-AML progression, the critical role of vigilant CMV surveillance, and the nuanced approach needed for treatment, balancing efficacy against potential side effects. The successful navigation of these complexities offers valuable insights for similar cases."
Journal • Acute Graft versus Host Disease • Acute Kidney Injury • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Nephrology • Ocular Inflammation • Oncology • Ophthalmology • Retinal Disorders • Transplantation • CD34 • TP53
|
|
Enas Abdallah; Kevin Harvey; Mamta Patel; Shivan Shah; Srijit Paul; Steven A Benyahia; Sunny Kahlon; Yusuf Aboul-Nasr
|